VitriVax Closes $87M Series C to Push Lyme Vaccine Into Human Trials
VitriVax raised an oversubscribed $87M Series C led by F-Prime, NEA, RA Capital and Sanofi Ventures to take its single-dose Lyme disease vaccine candidate into first-in-human trials.
